Key result
SGLT2i reduces CV death or HF hospitalization ~27% in HFrEF, showing similar effects to ARNI.
Why the study?
The study aimed to determine the effects of SGLT2i in HFrEF, compare SGLT2i with ARNI, and evaluate whether combining SGLT2i and ARNI provides greater benefit than monotherapy.
Does SGLT2i or combination of SGLT2i and ARNI reduce cardiovascular death or hospitalization for heart failure in patients with HFrEF compared to placebo or ARNI monotherapy?
Systematic Review
Does SGLT2i or combination of SGLT2i and ARNI reduce cardiovascular death or hospitalization for heart failure in patients with HFrEF compared to placebo or ARNI monotherapy?
SGLT2i and ARNI have similar efficacy in reducing cardiovascular events in HFrEF, but their combination provides superior cardiovascular protection compared to ARNI monotherapy.
Answers are grounded in this paper and cite their sources.
SGLT2i matches ARNI on CV death or HF hospitalization in HFrEF; supports combination over monotherapy and reinforces quadruple therapy.
AIMS: This study aimed to determine the effects of sodium-glucose cotransporter-2 inhibitor (SGLT2i) in heart failure with reduced ejection fraction (HFrEF), compare the effect of SGLT2i with angiotensin receptor neprilysin inhibitor (ARNI), and find whether combination of SGLT2i and ARNI is better than monotherapy. METHODS AND RESULTS: Embase, Medline, and Cochrane Central Registry of Controlled Trials were searched for randomized controlled trials evaluating SGLT2i or ARNI in HFrEF. And a total of six trials were included. SGLT2i was found to significantly reduce the risk of cardiovascular death or hospitalization for heart failure by 27% [hazard ratio (HR) 0.73, 95% confidence interval (CI) 0.67-0.80], hospitalization for heart failure by 31% (HR 0.69, 95% CI 0.62-0.77), cardiovascular death by 16% (HR 0.84, 95% CI 0.74-0.95), and all-cause death by 16% (HR 0.84, 95% CI 0.75-0.94) in HFrEF only with a statistically higher risk of genital infection (risk ratio (RR) 2.78, 95% CI 1.46-5.29). The reduction in cardiovascular death or hospitalization for heart failure was of similar magnitude in patients with or without diabetes mellitus (HR 0.71, 95% CI 0.64-0.80 vs. HR 0.75, 95% CI 0.65-0.87) using SGLT2i. Indirect treatment comparison showed that SGLT2i and ARNI had similar effects on primary outcome (HR 0.93, 95% CI 0.82-1.06). And combination of SGLT2i and ARNI achieved a better prognosis performance (HR 0.68, 95% CI 0.53-0.89) compared with ARNI monotherapy. CONCLUSIONS: SGLT2i could safely reduce cardiovascular death or hospitalization for heart failure in HFrEF regardless of diabetes mellitus status. SGLT2i and ARNI demonstrate similar effects, while combination of SGLT2i and ARNI results in a better cardiovascular protective effect.
No takes yet. Share an insight, caveat, or question.
Yan et al. (2021) conducted a systematic review in Heart failure with reduced ejection fraction (HFrEF). SGLT2i vs. ARNI was evaluated on Cardiovascular death or hospitalization for heart failure (HR 0.73, 95% CI 0.67-0.80). SGLT2i reduced the risk of cardiovascular death or hospitalization for heart failure by 27% in HFrEF, demonstrating similar effects to ARNI.
Synapse has enriched 10 related papers. Consider them for comparative context: